Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86925 trials found · Page 86 of 4347
-
New pill aims to keep pancreatic cancer from coming back after treatment
Disease control Recruiting nowThis phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is a…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New drug trial targets Tough-to-Treat breast cancer in the brain
Disease control OngoingThis is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed o…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Breakthrough fetal surgery uses placental stem cells to help babies with spina bifida walk
Disease control Recruiting nowSpina bifida, or myelomeningocele (MMC), is a birth defect that results in paralysis, excess fluid on the brain (hydrocephalus), and impaired ability to urinate and have bowel movements normally. In a previous study (the MOMS trial), surgery before birth (in-utero/fetal surgery) …
Phase: PHASE1, PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThe purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) particip…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Promising Gene-Targeted drug for ALS enters final trial phase
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC
-
New drug combo tested in major trial for Tough-to-Treat ovarian cancer
Disease control CompletedThe standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance. In patients with platinum-resistant or refractory ovarian cancer, effective treatment options are limited and t…
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
New radiation drug trial aims to control advanced prostate cancer
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a c…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC
-
New hope for kids with tough cancers: trial tests Double-Team drug strategy
Disease control Recruiting nowThe phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and partic…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Cheaper CAR-T therapy could expand access for lymphoma patients
Disease control Recruiting nowChimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory large B-cell lymphomas (R/R LBCLs) since 2018. However, high cost of commercial products limits their application in real-world clinical practice. Academic approach to manufacturi…
Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
Immunotherapy before standard treatment may boost survival in esophageal cancer
Disease control OngoingThe objective of this clinical trial is to determine whether the addition of immunotherapy combined with chemotherapy before chemoradiotherapy can increase the survival rate of patients with esophageal cancer. It will also assess the safety of this regimen. The primary questions …
Phase: PHASE3 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Can we wake and kill sleeping breast cancer cells? new trial aims to find out
Disease control Recruiting nowThis clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
New procedure offers hope for High-Risk heart patients, avoiding repeat Open-Heart surgery
Disease control CompletedThe Renato® transcatheter valve-in-valve system, developed by Balance Medical, is undergoing a multicenter registry trial across China. The study enrolls patients whose previously implanted surgical or transcatheter bioprosthetic valves have deteriorated and who are at high risk …
Phase: NA • Sponsor: Beijing Balance Medical Technology Co., Ltd • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingIn this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New hope for tough stomach cancers: advanced drug trial seeks to extend lives
Disease control OngoingThis study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-cont…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
New vaccine combo fights back against Treatment-Resistant skin cancer
Disease control CompletedThis is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unre…
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New Alzheimer's pill shows promise in slowing cognitive decline for High-Risk group
Disease control CompletedThis study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New engineered immune cell therapy tested for Tough-to-Treat blood cancer
Disease control OngoingA Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Apr 06, 2026 14:20 UTC
-
Major trial tests common diabetes pill as potential Alzheimer's slowing treatment
Disease control CompletedThis study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
New drug duo aims to hold back advanced prostate cancer longer
Disease control OngoingThe purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New combo therapy trial aims to boost survival for tough esophageal cancer
Disease control OngoingThis is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chem…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC